Topic: drug manufacturing
China FDA will take a new form; Celltrion's manufacturing issues might be worse than Teva hoped; Wuxi NextCODE and Google Cloud partner up.
Takeda, which recently announced a deal to buy stem cell therapy biotech TiGenix, will build a plant in Ireland to produce the treatment.
Takeda made two R&D deals, China's crackdown on pollution causes pharma supply issues, Merck KGaA plans production expansions in Asia.
Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
GSK is asked for more about its China bribery scandal, AZ made two health-tech deals in China, Samsung BioLogics' reported sales growth.
Sanofi Genzyme, which specializes in rare diseases, said it will let go of 130 workers at its Allston Landing biomanufacturing facility in Boston.
Shire, which decided to produce some of its drug Cinryze itself after contractor problems resulted in a shortage, will start production this quarter.
With plans for further expansion in China, Japan’s Eisai has opened a new solid dose plant in Suzhou.
Athenex is moving forward with a project to build a $210 million manufacturing plant in New York that will be financed primarily by the state.